KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Sarepta Therapeutics (SRPT) over the last 13 years, with Q3 2025 value amounting to $239.0 million.

  • Sarepta Therapeutics' Long-Term Investments fell 7978.52% to $239.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $239.0 million, marking a year-over-year decrease of 7978.52%. This contributed to the annual value of $133.2 million for FY2024, which is 194018.69% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Long-Term Investments of $239.0 million as of Q3 2025, which was down 7978.52% from $324.1 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Long-Term Investments high stood at $1.2 billion for Q3 2024, and its period low was $6.5 million during Q4 2023.
  • For the 5-year period, Sarepta Therapeutics' Long-Term Investments averaged around $141.1 million, with its median value being $33.9 million (2024).
  • As far as peak fluctuations go, Sarepta Therapeutics' Long-Term Investments skyrocketed by 607421.28% in 2024, and later tumbled by 7978.52% in 2025.
  • Sarepta Therapeutics' Long-Term Investments (Quarter) stood at $34.9 million in 2021, then dropped by 10.23% to $31.3 million in 2022, then tumbled by 79.16% to $6.5 million in 2023, then surged by 1940.19% to $133.2 million in 2024, then surged by 79.48% to $239.0 million in 2025.
  • Its Long-Term Investments stands at $239.0 million for Q3 2025, versus $324.1 million for Q2 2025 and $391.0 million for Q1 2025.